Solvay
2019 Annual Integrated Report

In 2019 total depreciation, amortization and impairment losses amount to € 1,906 million, of which:

  • straight-line depreciation and amortization of € 1,032 million for continuing operations including:
  • cost of goods sold (€ 641 million);
  • administrative costs (€ 110 million);
  • research and development costs (€ 83 million);
  • other (€ 198 million), including € 182 million for PPA amortization (see note F4 Other operating gains and losses);
  • net impairment loss of € 873 million for continuing operations, due to the impairment on Novecare Oil & Gas business (€ (825) million), and on other non-performing assets (€ (26) million), mainly due to the impairment of previously capitalized items related to the Group’s simplification and transformation program (see note F5 Results from portfolio management and reassessments, legacy remediation and major litigations).

The increase in the straight-line depreciation and amortization in 2019 compared to 2018 is mainly related to the adoption of IFRS 16 Leases.

In 2018 total depreciation, amortization and impairment losses amount to € 944 million, of which: